When VEGF-targeted therapies are discontinued, the tumor vasculature is rapidly reestablished [56] and continuation of Bevacizumab treatment beyond progression was associated with greater benefit in terms of OS [57]. This evidence concerns the gene VEGFA and neoplasm.